Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares Bought by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC boosted its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 9.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,709 shares of the medical instruments supplier’s stock after buying an additional 778 shares during the period. Motley Fool Asset Management LLC owned 0.16% of Mesa Laboratories worth $912,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Swiss National Bank lifted its stake in Mesa Laboratories by 1.7% during the 3rd quarter. Swiss National Bank now owns 11,802 shares of the medical instruments supplier’s stock worth $1,240,000 after acquiring an additional 200 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Mesa Laboratories by 23.1% in the 3rd quarter. SG Americas Securities LLC now owns 2,928 shares of the medical instruments supplier’s stock valued at $308,000 after acquiring an additional 549 shares during the last quarter. Eagle Asset Management Inc. increased its holdings in shares of Mesa Laboratories by 0.6% in the 3rd quarter. Eagle Asset Management Inc. now owns 111,979 shares of the medical instruments supplier’s stock valued at $11,766,000 after acquiring an additional 630 shares during the last quarter. Qube Research & Technologies Ltd increased its holdings in shares of Mesa Laboratories by 6.2% in the 3rd quarter. Qube Research & Technologies Ltd now owns 17,968 shares of the medical instruments supplier’s stock valued at $1,888,000 after acquiring an additional 1,042 shares during the last quarter. Finally, Jump Financial LLC increased its holdings in shares of Mesa Laboratories by 77.4% in the 3rd quarter. Jump Financial LLC now owns 3,293 shares of the medical instruments supplier’s stock valued at $346,000 after acquiring an additional 1,437 shares during the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

Mesa Laboratories Stock Performance

Shares of NASDAQ MLAB traded up $1.39 during trading hours on Friday, reaching $103.19. The stock had a trading volume of 19,542 shares, compared to its average volume of 47,456. The firm has a market cap of $556.19 million, a price-to-earnings ratio of 598.86 and a beta of 0.83. The company has a current ratio of 2.68, a quick ratio of 1.86 and a debt-to-equity ratio of 0.58. Mesa Laboratories, Inc. has a fifty-two week low of $82.86 and a fifty-two week high of $172.80. The firm has a 50-day moving average of $105.02 and a 200-day moving average of $99.71.

Mesa Laboratories (NASDAQ:MLAB) last announced its earnings results on Monday, February 5th. The medical instruments supplier reported $1.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.47 by ($0.01). Mesa Laboratories had a net margin of 0.45% and a return on equity of 7.41%. The firm had revenue of $53.47 million during the quarter, compared to analyst estimates of $54.90 million. Equities research analysts predict that Mesa Laboratories, Inc. will post 6.15 earnings per share for the current year.

Mesa Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 31st will be given a dividend of $0.16 per share. The ex-dividend date is Friday, May 31st. This represents a $0.64 dividend on an annualized basis and a yield of 0.62%. Mesa Laboratories’s payout ratio is 376.49%.

Analyst Upgrades and Downgrades

Separately, Evercore ISI upped their target price on Mesa Laboratories from $124.00 to $130.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.